COMP <GO>
OCUL vs PAHC // EV/EBITDA & P/E VALUATION
Ocular Therapeutix Inc. (NASDAQ) VS. Phibro Animal Health Corporation (Class A) (NASDAQ) • 15-METRIC TALLY: OCUL 3
— PAHC 8
■ METRIC PARITY
LAST: $7.31 (+0.27%) • MKT CAP: $1.61B
valuation
—
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
valuation
19.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCUL VS. PAHC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OCUL | PAHC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 30.90% | +56.40 | OCUL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 9.90% | -44.90 | PAHC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 19.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.51% | 5.08% | -18.59 | PAHC | /fcf-yield <GO> |
| Operating Margin | -60.00% | 8.50% | -68.50 | PAHC | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.70% | -63.70 | PAHC | /net-margins <GO> |
| Revenue Growth (YoY) | -18.50% | 27.40% | -45.90 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.23% | -1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.31 | 2.87 | +1.44 | OCUL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.3 | 56.9 | -14.60 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 27.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $1.58B | $27.6M | OCUL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OCUL REV | PAHC REV | OCUL GROSS % | PAHC GROSS % | OCUL FCF | PAHC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $52.0M | $1.30B | 87.3% | 30.9% | -$216.9M | $80.1M |
| FY 2024 | $63.7M | $1.02B | 91.2% | 30.8% | -$136.0M | $87.6M |
| FY 2023 | $58.4M | $977.9M | — | — | -$70.2M | $13.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCUL // BETA —
PAHC // BETA —